Sentinel NOSE Study: Prospective Registration Study on the Sentinel Node Procedure for Bulky Squamous Cell Carcinoma of the Nasal Vestibule.
NCT05637307 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10
Last updated 2024-12-17
Summary
Management of the neck in Wang cT1-T2N0 nasal vestibule carcinoma (NVC) has been an ongoing point of discussion. As the disease is rare publications are scarce and published regional recurrence rates vary widely between 0% up to 23%. In general, literature recommends adequate radiological neck staging followed by a watchful waiting policy, as overall regional recurrence rates are low (5-10%).
However, according to recent findings, a subset of patients with large or voluminous cT1-T2N0 NVC is deemed at high risk of nodal involvement (20-40% regional recurrence) but receive no elective treatment, although it is well known that presence of nodal metastases impacts the prognosis of head and neck cancer (HNC) dramatically. Whereas elective neck dissection may be too aggressive, sentinel node biopsy (SNB) has been proven a reliable and safe alternative to bridge the gap between imaging and neck dissection.
SNB is currently routinely employed in most HNC centres in the Netherlands and is considered state of the art care, but its application in HNC is limited to oral cavity carcinoma and squamous cell carcinoma of the skin. Following the observation of increased risk of (occult) nodal metastases and regional recurrence in bulky tumors, the sentinel node procedure seems ideally suited for cT1-T2N0 NVC patients. Its superficial tumor localization is easily accessible for peritumoral Tc-99m-nanocolloid-ICG tracer injection. The purpose of this prospective registration study is to document the clinical introduction of the sentinel node procedure for bulky nasal vestibule carcinoma in our centre by protocol, and to identify and address possible unexpected difficulties specific for this tumor site. Ultimately, the goal will be routine and wide implementation of SNB in the NVC subgroup known to be at risk of nodal involvement, as a means to improve regional disease staging and control.
Objective: To prospectively document the introduction of the sentinel node procedure for bulky cT1-T2N0 nasal vestibule carcinoma in patients at risk of nodal involvement.
Study design: Single centre prospective registration study. To be extended with a second centre.
Study population: Patients with Wang cT1-T2N0 squamous cell carcinoma of the nasal vestibule, with tumor diameter ≥1.5 cm and/or tumor volume ≥1.5 cm3, with a WHO performance score of 2 or lower and no history of previous surgery or radiotherapy of the neck.
Interventions: 1. Subcutaneous peritumoral radioactive tracer injection followed by lymphoscintigraphy and Single Photon Emission Computed Tomography (SPECT) imaging for sentinel lymph node visualization.
2\. Surgical sentinel node biopsy and histopathological examination of harvested nodes following the abovementioned imaging.
Main study parameters/endpoints: The primary endpoint of this study will be successful identification of sentinel nodes on lymphoscintigraphy and SPECT imaging. The procedure will be considered feasible when one or more sentinel nodes can be identified and localized in at least 7 out of the 10 patients..
Conditions
- Squamous Cell Carcinoma of the Nasal Vestibule
Interventions
- PROCEDURE
-
Sentinel node procedure
Injection of radio-active tracer in the tumor before brachytherapy treatment, visualization of sentinel nodes by SPECT, and extirpation of sentinel nodes by surgery
Sponsors & Collaborators
-
Radboud University Medical Center
lead OTHER
Principal Investigators
-
Hans Kaanders, Prof., PhD, MD · Radboud University Medical Center
Study Design
- Allocation
- NA
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-15
- Primary Completion
- 2024-01-15
- Completion
- 2024-01-16
Countries
- Netherlands
Study Locations
More Related Trials
-
Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients
NCT05673577 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Nivolumab in Patients With Head and Neck Cancer.
NCT04050761 ·Status: COMPLETED
-
Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck
NCT06990737 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Radiotherapy for Sinonasal Malignancy
NCT06617910 ·Status: ACTIVE_NOT_RECRUITING
-
Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot
NCT03010553 ·Status: UNKNOWN ·Phase: PHASE2
-
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck
NCT04664582 ·Status: UNKNOWN ·Phase: NA
-
Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
NCT03667482 ·Status: COMPLETED ·Phase: PHASE1
-
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer
NCT07065630 ·Status: RECRUITING ·Phase: PHASE2
-
International Prospective Multicentre Study That Evaluate the Sentinel Lymph Node Detection Rate in Patients With First Local Recurrent Scamous Cell Carcinoma of the Vulva.
NCT07023601 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma
NCT05151588 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
NCT04146181 ·Status: UNKNOWN ·Phase: PHASE2
-
Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC
NCT05814666 ·Status: TERMINATED ·Phase: PHASE2
-
Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
NCT05608369 ·Status: WITHDRAWN ·Phase: PHASE2
-
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05076942 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)
NCT07063212 ·Status: RECRUITING ·Phase: PHASE2
-
Reducing Excision Margins After Neoadjuvant Chemoimmunotherapy for HPV Negative Resectable Locally Advanced HNSCC
NCT05459415 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma
NCT06170697 ·Status: UNKNOWN ·Phase: PHASE2
-
Identification of Pattern and Factors Affecting Recurrence in Head and Neck Carcinoma
NCT06465030 ·Status: RECRUITING
-
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
NCT03422536 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy and Cetuximab in Treating Patients With Recurrent Head and Neck Cancer
NCT00891904 ·Status: TERMINATED ·Phase: NA
-
Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC
NCT02047201 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS
NCT05879484 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
NCT03370276 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada
NCT02705833 ·Status: COMPLETED
-
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
NCT05743270 ·Status: WITHDRAWN ·Phase: PHASE2